-
EP3956034
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3956034
| EP3956034 - ANTAGONISTS ANTI-CD7 ANTIBODIES [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 21.01.2022 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 23.10.2020 | ||
| Former | unknown Status updated on 27.04.2020 | Most recent event Tooltip | 13.03.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Kymab Limited The Bennet Building (B930) Babraham Research Campus Cambridge CB22 3AT / GB | [2022/08] | Inventor(s) | 01 /
LEE, E-Chiang Kymab Limited The Bennet Building (B930) Babraham Research Campus Cambridge CB22 3AT / GB | 02 /
BORHIS, Gwenoline Kymab Limited The Bennet Building (B930) Babraham Research Campus Cambridge CB22 3AT / GB | 03 /
VAN KRINKS, Cassandra Kymab Limited The Bennet Building (B930) Babraham Research Campus Cambridge CB22 3AT / GB | 04 /
HEPBURN, Lucy Kymab Limited The Bennet Building (B930) Babraham Research Campus Cambridge CB22 3AT / GB | 05 /
BAYLISS, Luke Kymab Limited The Bennet Building (B930) Babraham Research Campus Cambridge CB22 3AT / GB | 06 /
KOSMAC, Miha Kymab Limited The Bennet Building (B930) Babraham Research Campus Cambridge CB22 3AT / GB | [2022/08] | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [N/P] |
| Former [2022/08] | Potter Clarkson The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB | Application number, filing date | 20719325.1 | 17.04.2020 | [2022/08] | WO2020GB50976 | Priority number, date | GB20190005552 | 18.04.2019 Original published format: GB 201905552 | [2022/08] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020212710 | Date: | 22.10.2020 | Language: | EN | [2020/43] | Type: | A1 Application with search report | No.: | EP3956034 | Date: | 23.02.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.10.2020 takes the place of the publication of the European patent application. | [2022/08] | Search report(s) | International search report - published on: | EP | 22.10.2020 | Classification | IPC: | A61P35/02, C07K16/28 | [2022/08] | CPC: |
A61P35/02 (EP,US);
C07K16/2803 (EP,US);
A61K39/39558 (US);
A61K45/06 (US);
A61K2039/505 (EP,US);
C07K2317/21 (EP);
C07K2317/33 (EP,US);
C07K2317/34 (US);
C07K2317/565 (US);
C07K2317/70 (EP);
C07K2317/732 (EP,US);
C07K2317/734 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/08] | Title | German: | ANTI-CD7 -ANTIKÖRPER ANTAGONISTEN | [2022/08] | English: | ANTAGONISTS ANTI-CD7 ANTIBODIES | [2022/08] | French: | ANTICORPS ANTI-CD7 ANTAGONISTES | [2022/08] | Entry into regional phase | 04.10.2021 | National basic fee paid | 04.10.2021 | Designation fee(s) paid | 04.10.2021 | Examination fee paid | Examination procedure | 04.10.2021 | Examination requested [2022/08] | 04.10.2021 | Date on which the examining division has become responsible | 13.05.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 20.03.2022 | Renewal fee patent year 03 | 14.03.2023 | Renewal fee patent year 04 | 13.03.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO9531212 (UNIV PENNSYLVANIA [US]) [X] 1,6 * page 23, line 37 - page 24, line 7 * * claim 5 * [I] 2-5,7-28; | [XI] - GRAMATZKI M ET AL, "158: T-ALL therapy in a preclinical model: The CD7 antibody TH-69 is highly active", ANNALS OF HEMATOLOGY; ANNUAL MEETING OF THE GERMAN AND THE AUSTRIAN SOCIETY OF HEMATOLOGY AND ONCOLOGY, BERLIN, DE; ESSEN, GERMANY, (19930101), vol. 67, no. SUPPL. 1, doi:10.1007/BF01714878, ISSN 0939-5555, page A41, XP009521517 [X] 1,6 * the whole document * [I] 2-5,7-28 DOI: http://dx.doi.org/10.1007/BF01714878 | [I] - HIRATA R ET AL, "Differential prognosis detected by immunophenotyping in acute lymphoblastic leukemia of childhood with poor prognostic factors", JAPANESE JOURNAL OF CLINICAL ONCOLOGY, TOKYO, JP, (19870101), vol. 17, no. 3, doi:10.1093/OXFORDJOURNALS.JJCO.A039206, ISSN 0368-2811, pages 229 - 236, XP009521518 [I] 1-14,24-28 * the whole document * DOI: http://dx.doi.org/10.1093/oxfordjournals.jjco.a039206 | [I] - JANSEN ET AL, "Successful treatment of human acute T-cell leukemia in SCID mice using the anti- CD7 -deglycosylated ricin A-chain immunotoxin DA7", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, AACR ANNUAL MEETING 2018; APRIL 14-18, 2018; CHICAGO, IL, (19920301), ISSN 0008-5472, XP002077287 [I] 1-28 * the whole document * | [I] - VALLERA D A ET AL, "Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, (19961016), vol. 197, no. 1, doi:10.1016/0022-1759(96)00127-5, ISSN 0022-1759, pages 69 - 83, XP004021292 [I] 1-28 * the whole document * DOI: http://dx.doi.org/10.1016/0022-1759(96)00127-5 | [I] - JINLE TANG ET AL, "Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells", ONCOTARGET, (20160412), vol. 7, no. 23, doi:10.18632/oncotarget.8710, XP055547936 [I] 1-28 * the whole document * DOI: http://dx.doi.org/10.18632/oncotarget.8710 | by applicant | US4675187 | WO2008003103 | WO2015103072 | - HEINRICH G, "Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions", J Immunol., (19891201), vol. 143, no. 11, pages 3589 - 97 | - BAUM WSTEININGER HBAIR HJBECKER WHANSEN-HAGGE TEKRESSEL M et al., "Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL", Br J Haematol., (19961100), vol. 95, no. 2, pages 327 - 38 | - DIGIAMMARINO et al., "Design and generation of DVD-lgTM molecules for dual-specific targeting", Meth. Mo. Biol., (20120000), vol. 889, doi:10.1007/978-1-61779-921-1_9, pages 145 - 156, XP009169361 DOI: http://dx.doi.org/10.1007/978-1-61779-921-1_9 | - CHOTHIA, C.LESK, A. M., "Canonical structures for the hypervariable regions of immunoglobulins", J. Mol. Biol., (19870000), vol. 196, doi:10.1016/0022-2836(87)90412-8, pages 901 - 917, XP024010426 DOI: http://dx.doi.org/10.1016/0022-2836(87)90412-8 | - LEFRANC, M. P., "Unique database numbering system for immunogenetic analysis", Immunol. Today, (19970000), vol. 18, doi:10.1016/S0167-5699(97)01163-8, page 50, XP004093509 DOI: http://dx.doi.org/10.1016/S0167-5699(97)01163-8 | - Fundamental Immunology, Raven Press, (19890000), pages 332 - 336 | - SUCKAUDETLEV et al., "Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping", Proceedings of the National Academy of Sciences, (19900000), vol. 87, no. 24, pages 9848 - 9852, XP055483256 | - KABAT et al., Ann. NY Acad. Sci., (19710000), vol. 190, pages 382 - 391 | - Methods in Enzymology: Guide to Molecular Cloning Techniques, Academic Press Inc., (19870000), vol. 152 | - Methods in Cell Biology, Academic Press, (19980000), vol. 57 | - LEE, JEONG HYUN et al., "Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike", Nature communications, (20150000), vol. 6, doi:10.1038/ncomms9167, XP055234636 DOI: http://dx.doi.org/10.1038/ncomms9167 | - NIEDERFELLNERGERHARD et al., "Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type l/ll distinction of CD20 antibodies", Blood, (20110000), vol. 118, no. 2, pages 358 - 367 | - DILLON SP, "Systemic lupus erythematosus and C1q: A quantitative ELISA for determining C1q levels in serum", Biotechnol J., (20090800), vol. 4, no. 8, pages 1210 - 4 | - FIGLAAANDAHL, EM et al., J Immunol., (20030000), vol. 170, pages 2349 - 2355 | - WARE REHAYNES BF., "T cell CD7 mRNA expression is regulated by both transcriptional and post-transcriptional mechanisms", Int Immunol., (19930200), vol. 5, no. 2, pages 179 - 87 | - BARCENA AMUENCH MOGALY AHCUPP JRONCAROLO MGPHILLIPS JH et al., "Phenotypic and functional analysis of T-cell precursors in the human fetal liver and thymus: CD7 expression in the early stages of T- and myeloid-cell development", Blood, (19931201), vol. 82, no. 11, pages 3401 - 14 | - HAO Q-LGEORGE AAZHU JBARSKY LZIELINSKA EWANG X et al., "Human intrathymic lineage commitment is marked by differential CD7 expression: identification of CD7- lympho-myeloid thymic progenitors", Blood, (20080201), vol. 111, no. 3, pages 1318 - 26 | - REINHOLD U, "Abken H. CD4+ CD7- T cells: a separate subpopulation of memory T cells?", J Clin Immunol., (19970700), vol. 17, no. 4, pages 265 - 71 | - WARE REHART MKHAYNES BF., "Induction of T cell CD7 gene transcription by nonmitogenic ionomycin-induced transmembrane calcium flux", J Immunol Baltim Md 1950, (19911015), vol. 147, no. 8, pages 2787 - 94 | - RABINOWICH HLIN WCHERBERMAN RBWHITESIDE TL., "Signaling via CD7 molecules on human NK cells. Induction of tyrosine phosphorylation and beta 1 integrin-mediated adhesion to fibronectin", J Immunol Baltim Md 1950, (19941015), vol. 153, no. 8, pages 3504 - 13, XP002156206 | - LEE DMSTAATS HFSUNDY JSPATEL DDSEMPOWSKI GDSCEARCE RM et al., "Immunologic characterization of CD7-deficient mice", J Immunol Baltim Md 1950, (19980615), vol. 160, no. 12, pages 5749 - 56 | - SEMPOWSKI GDLEE DMSCEARCE RMPATEL DDHAYNES BF., "Resistance of CD7-deficient mice to lipopolysaccharide-induced shock syndromes", J Exp Med., (19990315), vol. 189, no. 6, doi:10.1084/jem.189.6.1011, pages 1011 - 6, XP002924416 DOI: http://dx.doi.org/10.1084/jem.189.6.1011 | - CARRIERE DARCIER JMDEROCQ JMFONTAINE CRICHER G., "Antigenic modulation induced by four monoclonal antibodies adsorbed on gold particles (specificity anti-CD4, anti-CD5, anti-CD7, and anti-150-kDa antigen): Relationship between modulation and cytotoxic activity of immunotoxins", Exp Cell Res., (19890500), vol. 182, no. 1, doi:10.1016/0014-4827(89)90284-X, pages 114 - 28, XP024791022 DOI: http://dx.doi.org/10.1016/0014-4827(89)90284-X | - SHARMA LCMUIRHEAD NLAZAROVITS AL., "Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection: analysis beyond 4 years", Transplant Proc., (19970300), vol. 29, no. 1-2, pages 323 - 4, XP027382582 | - RAPPL GABKEN HMUCHE JMSTERRY WTILGEN WANDRE S et al., "CD4+CD7- leukemic T cells from patients with Sezary syndrome are protected from galectin-l-triggered T cell death", Leukemia, (20020500), vol. 16, no. 5, pages 840 - 5 | - PNG YTVINANICA NKAMIYA TSHIMASAKI NCOUSTAN-SMITH ECAMPANA D., "Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies", Blood Adv., (20171128), vol. 1, no. 25, doi:10.1182/bloodadvances.2017009928, pages 2348 - 60, XP055452690 DOI: http://dx.doi.org/10.1182/bloodadvances.2017009928 | - KITA KMIWA HNAKASE KKAWAKAMI KKOBAYASHI TSHIRAKAWA S et al., "Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma", Blood, (19930501), vol. 81, no. 9, pages 2399 - 405 | - ROHRS SSCHERR MROMANI JZABORSKI MDREXLER HGQUENTMEIER H., "CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation", J Hematol OncolJ Hematol Oncol., (20100414), vol. 3, doi:10.1186/1756-8722-3-15, page 15, XP021083341 DOI: http://dx.doi.org/10.1186/1756-8722-3-15 | - KEIZER MPKAMP AMAARTS CGEISLER JCARON HNVAN DE WETERING MD et al., "The High Prevalence of Functional Complement Defects Induced by Chemotherapy", Front Immunol., (20160000), vol. 7, page 420 | - DIEBOLDER CABEURSKENS FJDE JONG RNKONING RISTRUMANE KLINDORFER MA et al., "Complement is activated by IgG hexamers assembled at the cell surface", Science, (20140314), vol. 343, no. 6176, doi:10.1126/science.1248943, pages 1260 - 3, XP055268751 DOI: http://dx.doi.org/10.1126/science.1248943 | - HEINRICH GGRAM HKOCHER HPSCHREIER MHRYFFEL BAKBAR A et al., "Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions", J Immunol Baltim Md 1950, (19891201), vol. 143, no. 11, pages 3589 - 97 | - RAVANDI FARIBI AO'BRIEN SFADERL SJONES DFERRAJOLI A et al., "Phase II study of alemtuzumab in combination with pentostatin in patients with", J Clin Oncol Off J Am Soc Clin Oncol., (20091110), vol. 27, no. 32, pages 5425 - 30 | - HAAPANIEMI EBOTLA SPERSSON JSCHMIERER BTAIPALE J., "CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response", Nat Med., (20180700), vol. 24, no. 7, doi:10.1038/s41591-018-0049-z, pages 927 - 30, XP036542072 DOI: http://dx.doi.org/10.1038/s41591-018-0049-z | - KOSICKI MTOMBERG KBRADLEY A., "Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements", Nat Biotechnol., (20180900), vol. 36, no. 8, doi:10.1038/nbt.4192, pages 765 - 71, XP036929645 DOI: http://dx.doi.org/10.1038/nbt.4192 | - VAN VLIERBERGHE PFERRANDO A., "The molecular basis of T cell acute lymphoblastic leukemia", J Clin Invest., (20121000), vol. 122, no. 10, pages 3398 - 406 | - COUSTAN-SMITH EMULLIGHAN CGONCIU MBEHM FGRAIMONDI SCPEI D et al., "Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia", Lancet Oncol., (20090200), vol. 10, no. 2, doi:10.1016/S1470-2045(08)70314-0, pages 147 - 56, XP025940626 DOI: http://dx.doi.org/10.1016/S1470-2045(08)70314-0 | - MARKS D|PAIETTA EMMOORMAN AVRICHARDS SMBUCK GDEWALD G et al., "T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993", Blood, (20091210), vol. 114, no. 25, pages 5136 - 45 | - ALDOSS IBARGOU RCNAGORSEN DFRIBERG GRBAEUERLE PAFORMAN SJ., "Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific", Leukemia, (20170400), vol. 31, no. 4, pages 777 - 87 | - LEE E-CLIANG QALI HBAYLISS LBEASLEY ABLOOMFIELD-GERDES T et al., "Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery", Nat Biotechnol., (20140400), vol. 32, no. 4, pages 356 - 63 | - DE JONG RNBEURSKENS FJVERPLOEGEN SSTRUMANE KVAN KAMPEN MDVOORHORST M et al., "A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface", PLoS Biol., (20160100), vol. 14, no. 1, doi:10.1371/journal.pbio.1002344, page el002344, XP055268752 DOI: http://dx.doi.org/10.1371/journal.pbio.1002344 | - AGNUSDEI VMINUZZO SFRASSON CGRASSI AAXELROD FSATYAL S et al., "Therapeutic antibody targeting of Notchl in T-acute lymphoblastic leukemia xenografts", Leukemia, (20140200), vol. 28, no. 2, pages 278 - 88 | - JUNG LKROY AKCHAKKALATH HR., "CD7 augments T cell proliferation via the interleukin-2 autocrine pathway", Cell Immunol., (19920415), vol. 141, no. 1, doi:10.1016/0008-8749(92)90138-F, pages 189 - 99, XP024003200 DOI: http://dx.doi.org/10.1016/0008-8749(92)90138-F | - MARKIEWSKI MMLAMBRIS JD., "The role of complement in inflammatory diseases from behind the scenes into the spotlight", Am J Pathol., (20070900), vol. 171, no. 3, pages 715 - 27 | - KOLA ABAENSCH MBAUTSCH WHENNECKE MKLOS ACASARETTO M et al., "Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis", Immunotechnology Int J Immunol Eng., (19960600), vol. 2, no. 2, doi:10.1016/1380-2933(96)00425-3, pages 115 - 26, XP004052676 DOI: http://dx.doi.org/10.1016/1380-2933(96)00425-3 | - MATLUNG HLBABES LZHAO XWVAN HOUDT MTREFFERS LWVAN REES DJ et al., "Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis", Cell Rep., (20180626), vol. 23, no. 13, doi:10.1016/j.celrep.2018.05.082, pages 3946 - 3959, XP055603864 DOI: http://dx.doi.org/10.1016/j.celrep.2018.05.082 | - FRANKEL AELAVER JHWILLINGHAM MCBURNS UKERSEY JHVALLERA DA., "Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin", Leuk Lymphoma, (19970700), vol. 26, no. 3-4, pages 287 - 98 | - DEANGELO DJYU DJOHNSON JLCOUTRE SESTONE RMSTOPECK AT et al., "Nelarabine induces complete remissions in adults with relapsed or refractory", Blood, (20070615), vol. 109, no. 12, pages 5136 - 42 | - JAIN NLAMB AVO'BRIEN SRAVANDI FKONOPLEVA MJABBOUR E et al., "Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype", Blood, (20160414), vol. 127, no. 15, pages 1863 - 9 |